AMENDMENT TO
RULES COMMITTEE PRINT 118–10
OFFERED BY MS. JAYAPAL OF WASHINGTON

At the end of subtitle C of title VII, add the following new section:

SEC. 7. FUNDING FOR CONDUCT OF CERTAIN TRIALS RELATING TO CORBEVAX VACCINE.

(a) Authorization of Appropriations.—There is authorized to be appropriated $20,000,000 for the United States Army Medical Research and Development Command, including any subordinate entity of such Command, to conduct two phase-III clinical trials for the patent-free and openly licensed Corbevax vaccine (one trial with respect to the vaccine and one trial with respect to the booster for such vaccine), for the purpose of gauging the effectiveness and suitability of such vaccine and booster in reducing hospitalization and transmission rates of COVID–19.

(b) Funding.—

(1) Increase.—Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated in section 210 for Research, Development, Test, and Evaluation,
Army, as specified in the corresponding funding table in section 4201, for Medical Technology, line 026, is hereby increased by $20,000,000.

(2) OFFSET.—Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated in section 301 for Operations and Maintenance, as specified in the corresponding funding table in section 4301, for administration and service-wide activities, Office of the Secretary of Defense, line 490, is hereby reduced by $20,000,000.